Koninklijke DSM NV (OTCMKTS:RDSMY) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm currently has a $19.00 price objective on the stock. Zacks Investment Research’s target price points to a potential upside of 13.92% from the company’s current price.

According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “

Shares of Koninklijke DSM NV (OTCMKTS:RDSMY) traded down 0.494% during mid-day trading on Tuesday, hitting $16.596. The stock had a trading volume of 1,423 shares. The firm has a market cap of $11.58 billion, a PE ratio of 39.026 and a beta of 1.44. Koninklijke DSM NV has a 12 month low of $11.33 and a 12 month high of $17.88. The stock’s 50-day moving average is $17.06 and its 200 day moving average is $15.68.

About Koninklijke DSM NV

Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.

Receive News & Stock Ratings for Koninklijke DSM NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM NV and related stocks with our FREE daily email newsletter.